FLT3 and acute myeloid leukemia: Recently, a phase I/II trial of single-agent pexidartinib in R/R FLT3-ITD AML demonstrated an ORR of 21% and CR rate of 11%; furthermore, several patients were successfully bridged to transplant (116).